Use of flutter VRP1 in the management of patients with steroid-dependent asthma.
We have assessed a new positive expiratory pressure device, the Flutter VRP1, in 20 patients with moderately severe asthma. Patients were studied for an initial 1-week 'run-in' period, followed by 2 weeks of the flutter device in one of which the ball-bearing was removed from the bowl. Peak expiratory flow rates, salbutamol inhaler requirements and visual analogue scores were recorded daily. Ease of sputum expectoration showed a significant improvement after 6 days of the flutter device, but there were no differences in objective measurements of lung function nor in salbutamol use. The device may be a useful adjunct to asthma therapy.
Swift
G L
GL
Department of Chest Medicine, Llandough Hospital, Cardiff, UK.
Rainer
T
T
Saran
R
R
Campbell
I A
IA
Prescott
R J
RJ
D000328:Adult; D000368:Aged; D001249:Asthma / Q000503:physiopathology / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D008875:Middle Aged; D010366:Peak Expiratory Flow Rate; D011175:Positive-Pressure Respiration / Q000295:instrumentation*; D011239:Prednisolone / Q000008:administration & dosage
D011239:Prednisolone